These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 24606074

  • 1. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
    Lin TC, Lee CH, Yang CY, Yang YH, Lin SJ.
    J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC, Yang CY, Yang YH, Lin SJ.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [Abstract] [Full Text] [Related]

  • 3. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
    Lin TC, Yang CY, Kao Yang YH, Lin SJ.
    Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
    [Abstract] [Full Text] [Related]

  • 4. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
    Cheng TT, Yu SF, Hsu CY, Chen SH, Su BY, Yang TS.
    Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
    [Abstract] [Full Text] [Related]

  • 5. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY, Hsieh CF, Tsai YW, Huang WF.
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [Abstract] [Full Text] [Related]

  • 6. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
    Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS.
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2729-35. PubMed ID: 24758181
    [Abstract] [Full Text] [Related]

  • 7. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 Aug; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 8. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
    Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Solomon DH.
    Ann Intern Med; 2008 May 06; 148(9):637-46. PubMed ID: 18458276
    [Abstract] [Full Text] [Related]

  • 9. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
    Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL.
    Bone; 2007 Apr 06; 40(4):843-51. PubMed ID: 17182297
    [Abstract] [Full Text] [Related]

  • 10. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
    Hsiao FY, Huang WF, Chen YM, Wen YW, Kao YH, Chen LK, Tsai YW.
    Clin Ther; 2011 Nov 06; 33(11):1659-67. PubMed ID: 22018450
    [Abstract] [Full Text] [Related]

  • 11. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E, Lang A, Robbins S, Ström O.
    Calcif Tissue Int; 2011 Sep 06; 89(3):234-45. PubMed ID: 21695544
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP.
    Arch Intern Med; 2003 Oct 13; 163(18):2237-46. PubMed ID: 14557222
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May 13; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

  • 17. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
    Zarowitz BJ, Cheng LI, Allen C, O'Shea T, Stolshek B.
    J Am Med Dir Assoc; 2015 Apr 13; 16(4):341-8. PubMed ID: 25726417
    [Abstract] [Full Text] [Related]

  • 18. Benefits and risks of raloxifene by vertebral fracture status.
    Sontag A, Wan X, Krege JH.
    Curr Med Res Opin; 2010 Jan 13; 26(1):71-6. PubMed ID: 19908937
    [Abstract] [Full Text] [Related]

  • 19. Prevention and treatment of osteoporosis in women with breast cancer.
    Mincey BA, Moraghan TJ, Perez EA.
    Mayo Clin Proc; 2000 Aug 13; 75(8):821-9. PubMed ID: 10943237
    [Abstract] [Full Text] [Related]

  • 20. Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database.
    Tanaka S, Yamamoto T, Oda E, Nakamura M, Fujiwara S.
    J Bone Miner Metab; 2018 Jan 13; 36(1):87-94. PubMed ID: 28028633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.